On December 11, 2025 Apollomics Issued Formal Notice Of Termination To Edison Oncology Related To Development And Commercialization Of APL-122; Terminating Agreement On Basis That Edison Failed To Fulfill Certain Material Performance & Reporting Obligations; Co Does Not Expect Termination To Have Material Adverse Effect On Its Overall Financial Condition Or Results Of Operations

On December 11, 2025, Apollomics Inc. (the "Company") issued a formal notice of termination to Edison Oncology Holding Corporation ("Edison") regarding the Development and License Agreement dated January 31, 2021, which was subsequently amended on August 11, 2023 (collectively, the "Agreement"), related to the development and commercialization of APL-122 (also known as EO1001).

APL-122 is an oral, irreversible pan-ErbB inhibitor targeting EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) kinases. It is designed with superior blood-brain barrier penetration capabilities to treat ErbB-positive cancers, specifically addressing unmet needs in patients with central nervous system (CNS) metastases.

The Company is terminating the Agreement on the basis that Edison failed to fulfill certain material performance and reporting obligations required under the Agreement. Consequently, the Company has notified Edison of the termination of the collaboration and the Agreement, effective immediately.

The Company disputes any outstanding payment obligations claimed by Edison based on Edison's non-performance. The Company intends to vigorously defend its position and reserves all rights and remedies available under the Agreement and applicable law.

The Company does not expect this termination to have a material adverse effect on its overall financial condition or results of operations.